Format

Send to

Choose Destination
Br J Dermatol. 2016 Nov;175(5):1073-1075. doi: 10.1111/bjd.14662. Epub 2016 Aug 10.

A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.

Author information

1
Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia.
2
Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
3
NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
4
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
5
Department of Dermatology, Royal Prince Alfred Hospital, Sydney, Australia.
6
Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia.
7
Melanoma Institute Australia, Sydney, Australia.
8
Centre for Medical Psychology and Evidence-Based Decision-Making, University of Sydney, Sydney, Australia.
9
Sydney Medical School, Concord Clinical School, University of Sydney, Sydney, Australia.
10
Concord Repatriation General Hospital, Sydney, Australia.
11
Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia. diona.damian@sswahs.nsw.gov.au.
12
Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia. diona.damian@sswahs.nsw.gov.au.
13
Melanoma Institute Australia, Sydney, Australia. diona.damian@sswahs.nsw.gov.au.
PMID:
27061568
DOI:
10.1111/bjd.14662
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center